Allergen-Specific Child Immunotherapy: Current State of Affairs
The article is devoted to allergen-specific immunotherapy (ASIT) — the only etiopathogenic therapy method for allergic diseases. By promoting the formation of immunological tolerance, ASIT modifies the course of the disease, prevents the occurrence of new or the worsening of existing sensitizations,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2016-11-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839587060720074752 |
|---|---|
| author | E. A. Vishneva L. S. Namazova-Baranova A. A. Alekseeva L. R. Selimzyanova J. G. Levina K. E. Efendieva E. A. Dobrynina |
| author_facet | E. A. Vishneva L. S. Namazova-Baranova A. A. Alekseeva L. R. Selimzyanova J. G. Levina K. E. Efendieva E. A. Dobrynina |
| author_sort | E. A. Vishneva |
| collection | DOAJ |
| description | The article is devoted to allergen-specific immunotherapy (ASIT) — the only etiopathogenic therapy method for allergic diseases. By promoting the formation of immunological tolerance, ASIT modifies the course of the disease, prevents the occurrence of new or the worsening of existing sensitizations, thereby preventing the development of asthma, which is especially important for pediatric patients. The authors present the mechanism of action and its main features and conditions with regard to achieving the planned effect. Considered are the key contraindications to ASIT, the principles of selecting the appropriate allergen for the treatment and features of its introduction to both children with mono sensitization and children sensitive to the allergen group. Further prospects of research development and existing achievements of this medical technology are mentioned. |
| format | Article |
| id | doaj-art-a0de4beaf86b43f68fbed17815acd0ef |
| institution | Matheson Library |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2016-11-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-a0de4beaf86b43f68fbed17815acd0ef2025-08-03T19:21:26ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892016-11-0113440440810.15690/pf.v13i4.16161431Allergen-Specific Child Immunotherapy: Current State of AffairsE. A. Vishneva0L. S. Namazova-Baranova1A. A. Alekseeva2L. R. Selimzyanova3J. G. Levina4K. E. Efendieva5E. A. Dobrynina6Scientific Center of Children’s HealthScientific Center of Children’s Health; Sechenov First Moscow State Medical University; Pirogov Russian National Research Medical UniversityScientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityScientific Center of Children’s Health; Pirogov Russian National Research Medical UniversityScientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityScientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityScientific Center of Children’s HealthThe article is devoted to allergen-specific immunotherapy (ASIT) — the only etiopathogenic therapy method for allergic diseases. By promoting the formation of immunological tolerance, ASIT modifies the course of the disease, prevents the occurrence of new or the worsening of existing sensitizations, thereby preventing the development of asthma, which is especially important for pediatric patients. The authors present the mechanism of action and its main features and conditions with regard to achieving the planned effect. Considered are the key contraindications to ASIT, the principles of selecting the appropriate allergen for the treatment and features of its introduction to both children with mono sensitization and children sensitive to the allergen group. Further prospects of research development and existing achievements of this medical technology are mentioned.https://www.pedpharma.ru/jour/article/view/1450allergen immunotherapy sublingual allergen immunotherapyallergy pathogenetic therapyimmune tolerance induction and children |
| spellingShingle | E. A. Vishneva L. S. Namazova-Baranova A. A. Alekseeva L. R. Selimzyanova J. G. Levina K. E. Efendieva E. A. Dobrynina Allergen-Specific Child Immunotherapy: Current State of Affairs Педиатрическая фармакология allergen immunotherapy sublingual allergen immunotherapy allergy pathogenetic therapy immune tolerance induction and children |
| title | Allergen-Specific Child Immunotherapy: Current State of Affairs |
| title_full | Allergen-Specific Child Immunotherapy: Current State of Affairs |
| title_fullStr | Allergen-Specific Child Immunotherapy: Current State of Affairs |
| title_full_unstemmed | Allergen-Specific Child Immunotherapy: Current State of Affairs |
| title_short | Allergen-Specific Child Immunotherapy: Current State of Affairs |
| title_sort | allergen specific child immunotherapy current state of affairs |
| topic | allergen immunotherapy sublingual allergen immunotherapy allergy pathogenetic therapy immune tolerance induction and children |
| url | https://www.pedpharma.ru/jour/article/view/1450 |
| work_keys_str_mv | AT eavishneva allergenspecificchildimmunotherapycurrentstateofaffairs AT lsnamazovabaranova allergenspecificchildimmunotherapycurrentstateofaffairs AT aaalekseeva allergenspecificchildimmunotherapycurrentstateofaffairs AT lrselimzyanova allergenspecificchildimmunotherapycurrentstateofaffairs AT jglevina allergenspecificchildimmunotherapycurrentstateofaffairs AT keefendieva allergenspecificchildimmunotherapycurrentstateofaffairs AT eadobrynina allergenspecificchildimmunotherapycurrentstateofaffairs |